Chapter 89: Drugs That Weaken the Bacterial Cell Wall I: Penicillins

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when we talk about treating a patient, there is this expectation of mechanical precision,

like engineering.

Right, like fixing a machine.

Exactly.

You break your arm, the x -ray shows that jagged white line, and the doctor just points and says, you know, there it is.

You cast it, it heals, it feels very binary.

It is deeply comforting to have that kind of visible, perfectly categorized problem and solution.

I mean, we crave that certainty in medicine.

But then you step into the world of infectious diseases and antibiotics, and suddenly that x -ray machine is, well, it's useless.

We are looking at a microscopic landscape that is honestly an absolute battlefield.

Oh, completely.

It's chaotic down there.

And if you are a nursing student staring down a pharmacology exam right now, that battlefield probably looks less like medicine and more like a massive, terrifying spreadsheet of unpronounceable drug names.

Which is pretty much the absolute definition of diagnostic and pharmacological muddy waters.

Yeah.

So, welcome to a very special deep dive tailored specifically for you, the nursing student who is trying to make sense of all this.

Our mission today is singular.

We are going to master the chapter on penicillins from your textbook.

Leans pharmacology for nursing care, to be exact.

Chapter 89, no outside distractions, no fluff, just a pure student -friendly breakdown of the material unfolding in the exact logical order it appears in your reading.

We are taking that dense drug information and turning it into clear clinical reasoning.

And setting the stage for penicillins is actually quite fascinating, you know.

On paper, they are practically the ideal antibiotics.

Because they are so targeted, right?

Exactly.

They are incredibly active against a wide variety of bacteria, but their direct toxicity to the patient is astonishingly low.

I mean, they go after the invaders while leaving our human cells completely alone.

Which is amazing.

It is.

Their one major flaw is really just their tendency to trigger allergic reactions.

But aside from that, their safety profile is the reason they are so widely prescribed.

Okay, let's unpack this.

Before we talk about how to actually use these drugs at the bedside, we need to understand exactly how they kill bacteria, their mechanism of action.

And from what I understand, it all comes down to the bacterial cell wall.

It does, yeah.

Think about the environment inside a single bacterium.

The osmotic pressure in there is incredibly high.

Like a really overinflated balloon.

Perfect analogy.

If it weren't for a rigid structural cell wall surrounding it, the bacterium would just constantly take on water from its environment, swell up, and burst.

The cell wall is literally the only thing keeping it from exploding.

Wow.

And penicillins, which belong to a family called beta -lactam antibiotics, because they share this specific beta -lactam ring in their chemical structure, they target that exact wall.

Yes, along with cephalosporins, carbapenems, and astronome.

They all share that ring.

Right.

But here's what stood out to me.

They don't just destroy any bacterial wall.

They only work on bacteria that are actively growing and dividing.

Why is that?

That is a crucial concept for clinical reasoning.

To build and expand that wall, the bacteria use specific enzymes called transpeptidases.

You can think of them as microscopic bricklayers.

Okay, bricklayers.

Got it.

They create the cross -bridges that hold the wall's strands together, essentially laying the mortar to make it strong.

But because the bacterium is growing, it also needs to constantly remodel.

So it has to break things down, too.

Exactly.

It employs demolition cruise enzymes called auto -licens to break down old segments of the wall to make room for expansion.

Oh, I see.

So it's like a brick building under active construction.

You've got builders adding bricks and demolition crews knocking out walls to build an extension.

That is a perfect way to visualize it.

And penicillins are, well, they're a masterclass in sabotage.

They enter the construction site and do two things simultaneously.

What do they do?

First, they inhibit the transpeptidases, they fire the bricklayers.

Second, they disinhibit or activate the auto -licens.

They send the demolition crews into absolute overdrive.

Oh, wow.

So you stop the building and you accelerate the wrecking ball.

The wall weakens, the high osmotic pressure forces water to rush in, and the bacterium ruptures.

Boom.

It's a bactericidal process.

Total cell death.

But how does the penicillin molecule actually grab onto the bacteria to do this?

It targets very specific molecular anchors on the outer surface of the cytoplasmic membrane.

These are called penicillin binding proteins, or PBPs, specifically PBP1 and PBP3.

So the drug has to bind to these proteins to work.

It absolutely must.

And here's where it connects back to your earlier point.

Bacteria only express these PBPs when they are actively growing and dividing.

If the bacteria are just resting or dormant, the targets aren't there.

And the penicillin just floats right by.

Exactly.

Wait, so does this also explain why the drug is so safe for humans?

Because mammalian cells, our cells, don't have cell walls.

Precisely.

We don't have cell walls, which means we do not possess penicillin binding proteins.

The penicillin molecule literally has nothing to bind to in the human body.

It ignores our cells completely.

It's brilliant.

But that brings up a massive question.

If penicillins are so deadly to bacteria and so safe for us, why don't they just cure every single infection?

Because we are dealing with an evolutionary arms race.

Bacteria are living organisms, and they fight back.

They've actually developed three primary mechanisms of defense against our drugs.

Let's explore those defenses, because understanding them seems like the key to understanding why we use different drugs for different bugs.

Defense number one, the inability to reach the targets.

To grasp this, we have to look at figure 89 .2 in your text, the bacterial cell envelope.

Gram -positive bacteria have a very simple envelope, just two layers.

A cytoplasmic membrane and a thick cell wall.

Right, yeah.

And despite being thick, penicillins easily penetrate it to reach those binding proteins.

So standard penicillins are generally very active against gram -positive organisms.

But then you have the gram -negative bacteria, and they are basically wearing armor.

They absolutely are.

Gram -negative bacteria have three layers.

A cytoplasmic membrane, a thin cell wall, and then this extra hard -to -penetrate outer membrane.

And that outer membrane is what stops the drugs.

Yes.

It is highly selective.

It's filled with tiny porin channels, and only certain penicillins that are small enough or have the right chemical charge can actually cross it to reach the targets inside.

So that's the first defense of physical fortress.

What's the second?

Chemical warfare.

Inactivation by enzymes.

Wait.

So the bacteria actually secrete something that hunts down and destroys the drug?

They do.

They produce these enzymes called beta -lactamases.

And the ones that specifically hunt penicillins are called penicillinases.

How do they work?

They act like molecular scissors.

They find that crucial beta -lactam ring on the penicillin molecule and snip it open, rendering the drug completely inactive.

Gram -positive bacteria pump massive amounts of these scissors out into their surrounding environment to destroy the drug before it even gets close.

Gram -negative bacteria are a bit more stealthy.

What do they do?

They secrete small amounts of the enzyme just beneath their outer membrane into the para -plasmic space to ambush the drug once it sneaks inside.

And what's terrifying is that the genetic blueprints for these molecular scissors can be shared between bacteria, right?

Like trading weapons.

Yes, via plasmids.

They pass the resistance genes around rapidly.

Which brings us to the third defense mechanism.

And this is where we have to talk about the famous superbug, MRSA.

Methicillin -resistant Staphylococcus aureus, box 89 .1 in the text.

Exactly.

Bacteria can actually alter their own binding proteins.

So if the penicillin molecule is a key and the bacterial protein is a lock,

MRSA just changed the locks.

That is exactly what happened.

MRSA acquired new genes that code for low -affinity penicillin -binding proteins.

The penicillin shows up, but its key no longer fits the lock.

The drug can't bind, so it can't sabotage the wall.

This sounds like a massive clinical nightmare.

It is one of the biggest challenges in modern medicine.

And as a nurse, you need to differentiate the two distinct types of MRSA.

First, we have healthcare -associated MRSA or HCA MRSA.

That's the older one, right?

Emerged back in 1968, the USA 100 strain.

It's incredibly severe and it primarily preys on vulnerable populations.

Older patients, people with prolonged hospital stays or those with indwelling catheters.

And because it resists standard penicillins, you can't just use a stronger penicillin, right?

Because the locks are still changed.

Exactly.

You have to abandon the penicillin family entirely and bring in the heavy hitters.

You use drugs like intravenous vancomycin, linazolid, daptomycin, or ceftaraline.

Vancomycin doesn't care about the changed locks.

Right, because it attacks the cell wall using a completely different mechanism.

Okay, so that's the hospital strain.

What about the second type?

In 1981, community -associated MRSA or CA MRSA emerged the USA 300 strain.

It is genetically distinct.

It actually carries a dangerous gene called Pantinvalentine leukocidin that causes tissue necrosis.

But it spreads differently, doesn't it?

Yeah, unlike the hospital strain, it spreads through skin -to -skin contact or contaminated surfaces like sports equipment and razors.

We see it a lot in healthy populations.

And the treatment for that looks different.

Very different.

It usually manifests as skin infections, boils, or impetigo.

Often the doctor just needs to surgically drain the boil and no drugs are needed.

But if they do need antibiotics?

If antibiotics are required, we don't necessarily need the IV heavy hitters.

We can use targeted oral medications like trimethoprimsulfamethoxazole or clindamycin.

We can even use topical antibiotics like neupurosin or retipamamulin for people who are just carrying the bacteria harmlessly in their noses to stop them from spreading it.

So if bacteria are constantly throwing up physical armor,

deploying molecular scissors and changing their locks, how have our drugs evolved in response?

This is where pharmaceutical chemistry steps in.

All penicillins share a 6 -imidopenicillinic acid nucleus.

Table 89 .1 breaks this down, I think.

Yes.

By tweaking the side chains attached to that nucleus, chemists created four major classes of penicillins.

Narrow -spectrum that are penicillinase -sensitive, narrow -spectrum that are penicillinase -resistant, broad -spectrum, and extended -spectrum.

And the absolute prototype, the original drug that sets the standard for all the others, is penicillin G.

Yes.

Penicillin G is a narrow -spectrum agent.

It primarily targets those vulnerable gram -positive bacteria we mentioned, plus some gram -negative cotchi like nasaria, anaerobes, and spirochades, like the bacterium that causes syphilis.

But the way penicillin G is administered seems to trip up a lot of people.

It comes in four different salts, potassium, sodium, propane, and benzathine.

Why does the specific salt matter so much?

Because, as figure 89 .3 shows, the salt dictates how fast the drug is absorbed into the bloodstream.

Potassium and sodium salts act fast.

If you inject them intramuscularly, they peak in the blood in about 15 minutes.

And they can go IV, too.

Yes.

Because they are highly water -soluble, these are the only two salts that can be safely given intravenously.

Contrast that with the propane and benzathine salts.

I understand these are called repository preparations because they absorb incredibly slowly.

But I was shocked to read just how slow, if you give an IM injection of benzathine penicillin, it leaches into the blood over weeks.

Seems counterintuitive, right?

Why would you want a drug to absorb so slowly that the blood levels stay incredibly low?

Well, earlier you mentioned syphilis.

Is it because the syphilis bacterium is highly sensitive to penicillin?

But it takes a long time to eradicate.

You hit the nail on the head.

A single injection provides a low, persistent dose that relentlessly attacks the bacteria for weeks.

It's a silver bullet for that specific disease.

That makes sense.

But here's the critical safety warning for the bedside.

Because propane and benzathine salts have terrible water solubility, they must never be given IV.

Because injecting a poorly soluble, cloudy suspension directly into a vein would be disastrous.

It could easily be fatal.

Now, once penicillin G is absorbed, it distributes well.

But it only crosses into the CSF, joints, and eyes if inflammation is present.

Eventually, it's eliminated by the kidneys, mostly through active tubular secretion.

And what's the half -life?

In a healthy adult, it's incredibly short, just about 30 minutes.

Which means, from a nursing perspective, if the kidneys are failing, the drug isn't leaving the body.

Exactly.

You must monitor kidney function, especially in the elderly, the very young, or anyone with renal impairment.

If that 30 -minute half -life extends to hours, the drug accumulates to toxic levels.

So assuming the kidneys are fine, penicillin G is incredibly safe.

But we have to address the elephant in the room, allergies.

Yes.

Depending on the population, between 0 .4 % and 7 % of patients are allergic to penicillins.

The severity can range from a mild rash to life -threatening anaphylaxis.

A true allergic reaction requires prior exposure to the drug.

Your immune system has to have seen it before to build antibodies against it, right?

But I've heard stories of patients insisting, you know, I've never taken penicillin in my life, yet they still have a massive allergic reaction on their first dose.

How is that possible?

Because they were exposed without knowing it.

Penicillins are produced naturally by fungi in the environment.

Patients can also be exposed through traces of the antibiotic in foods of animal origin.

And here is a vital rule.

If a patient is allergic to one penicillin, they must be considered allergic to all penicillins due to cross -sensitivity.

They also have about a 1 % risk of being allergic to cephalosporins.

I really want to understand the mechanism here.

How does a molecule as tiny as penicillin trigger such a massive whole -body immune response?

It's a great question, because on its own, the penicillin molecule is actually too small for the immune system's radar to even pick up.

In medical terms, it's called a hapten.

OK, let me try an analogy.

Think of the penicillin molecule like a microscopic piece of Velcro floating through the bloodstream.

Because it's so small, the immune system ignores it.

But when the drug degrades, that Velcro physically sticks to one of your body's larger normal proteins.

I love that visual.

Yes, it covalently binds to a host protein.

Now you have this weird mutated protein -penicillin hybrid floating around.

This forms a complete antigen.

And the immune system spots that.

Exactly.

The radar finally spots it, recognizes it as a foreign threat, and sounds the alarm by forming antibodies.

And those antibodies,

specifically immunoglobulin E or IgE, are what trigger anaphylaxis.

Yes.

The safety alert in the text highlights this.

Anaphylaxis is rare, only 0 .004 to 0 .04 % of patients, but it has a 10 % mortality rate.

The airway swells, the lungs constrict, and blood pressure plummets.

So what's the treatment?

Management requires epinephrine and respiratory support.

So if a patient's chart says penicillin algae, what do we do?

It depends on the history.

If their past reaction was just a mild rash, the provider might still cautiously prescribe an oral cephalosporin.

But if there's any history of anaphylaxis, cephalosporins are entirely off the table.

You switch to a different class entirely.

Right.

Like vancomycin, erythromycin, or clendamycin.

We do have skin tests that can check a patient's current risk level by testing for major and minor determinants.

But those tests carry a risk of triggering anaphylaxis themselves, so they are only done with extreme caution.

Just briefly checking the person -centered care chart across the lifespan, it's generally safe in kids, right?

Yes.

Safe in kids.

No second or third trimester risk in pregnancy.

Amoxicillin is safe for breastfeeding.

And for older adults, just adjust the doses for their kidneys.

Speaking of risks, there is a major drug interaction I want to clarify.

I learned that because penicillins weaken the bacterial cell wall, they actually make it easier for other drugs like aminoglycoside, say gentamicin, to get inside the bacteria and finish the job.

The clinical logic there is perfectly sound.

We frequently use them together.

So to save time on the floor, we should just mix both drugs together in the same IV bag, right?

Absolutely not.

This is a classic nursing exam trap.

In the high concentrations found in an IV bag, penicillins will chemically interact with and physically inactivate the aminoglycosides.

Oh wow.

They neutralize each other before they even reach the patient.

You must administer them in completely separate IV solutions.

Once they are diluted in the patient's entire bloodstream, they play nicely together, but never let them mingle in the bag.

That is a critical takeaway.

Okay, so penicillin G is amazing, but it has flaws.

It gets destroyed by stomach acid and it gets chopped up by those bacterial enzyme scissors.

How did pharmaceutical chemists expand the arsenal to fix this?

They went back to that core chemical nucleus and started modifying it.

The simplest fix resulted in penicillin V.

What did they change?

They just tweaked the structure to make it acid stable.

Because of that one change, it completely replaces penicillin G for oral therapy and patients can even take it with meals.

Then we have the antistaphylococcal penicillins, like napcillin, oxicillin, and dicloxacillin.

These were specifically designed to resist the bacterial molecular scissors, right?

Yes.

Their entire job is to hunt down bacteria that produce penicillinases.

But just to be clear, does that include MRSA?

No, it does not.

Remember, MRSA didn't just use scissors, MRSA changed its binding locks.

So even though napcillin survives the scissors, it still can't bind to the MRSA lock.

Got it.

Next, the chemists created broad -spectrum penicillins, the amino penicillins, ampicillin and amoxicillin.

These are structurally modified to slip right through the porin channels of that thick gram -negative armor we talked about earlier.

Which vastly expands the types of infections they can treat, like H.

influenza, E.

coli, and salmonella.

Now, ampicillin was the first, but it tends to sit in the intestines and cause more rash and diarrhea.

And amoxicillin.

Amoxicillin was formulated to be more acid -stable, meaning almost all of it gets absorbed rapidly into the bloodstream.

Less drugs sitting in the gut means less diarrhea, making amoxicillin the preferred choice for oral use, though both of them are still inactivated by beta -lactamases.

And to go even bigger, we have the extended -spectrum penicillin, pipericillin.

This is the big gun.

It targets notoriously difficult bacteria like Pseudomonas aeruginosa.

Usually given IV, and often paired with an aminoglycoside to boost its power.

But again, separate IV bags.

Always separate bags.

But notice, even with all these modifications, many of these broader penicillins are still vulnerable to those bacterial enzyme scissors, which brings up a fascinating workaround.

If the bacteria are using penicillinases as scissors to cut up our drugs, can we just invent a drug that jams the scissors?

We can.

And we did.

This is the brilliance of beta -lactamase inhibitor combinations.

We take a standard penicillin, and we pair it with a decoy molecule, a beta -lactamase inhibitor like sulbactam, tozobactam, or clavulanic acid.

So the inhibitor doesn't actually kill the bacteria?

Not at all.

The inhibitor's only job is to distract and bind up the bacterial scissors.

It sacrifices itself so the actual penicillin is free to reach the wall and do its job.

That's incredibly clever.

It really is.

This creates the combination drugs you will see constantly in clinical practice.

Ampicillin with sulbactam is unicin.

Amoxicillin combined with clavulonate becomes augmentin.

Pipericillin with tozobactam becomes zocin.

And the inhibitor doesn't add any new side effects?

The inhibitor has virtually no toxicity of its own.

Any side effects are strictly from the penicillin part of the duo.

This all builds perfectly to the final step.

We know the pharmacology, the molecular building blocks, and the evolutionary arms race.

How does a nursing student translate all of this to actual bedside care?

It always starts with assessment.

Before you push that very first dose of any antibiotic,

what must you do?

Draw cultures.

Yes.

You must take microbiologic cultures before starting treatment.

You cannot blindly start treating an infection before you know exactly what bug is causing it, or you risk driving further resistance.

Then you verify their history.

Identify high -risk patients.

If they have an allergy to penicillins or cephalosporins, you flag it immediately.

And you monitor their kidney output to ensure the drug isn't accumulating.

What about actually giving the medication?

Well for IM injections, always aspirate to avoid injecting into an artery.

Keep patients under observation for 30 minutes after parenteral dosing, just in case of an allergic reaction.

I remember seeing a caution about dietary sodium restrictions.

Why does that matter for an antibiotic?

Think back to the salts.

If you are administering high -dose IV penicillin G using the sodium salt formulation,

you aren't just giving them an antibiotic, you are inadvertently pumping a massive amount of sodium into their bloodstream.

Oh, right.

If that patient has congestive heart failure, that sodium load could throw them into life -threatening fluid overload.

You have to connect the chemical formulation to the patient's underlying conditions.

That makes total sense.

And for oral administration, the general rule is to give it with a full glass of water one hour before or two hours after meals.

Right, except for the acid -stable ones like penicillin V, amoxicillin, and amoxicillin clavulinate, which can actually be taken with meals.

Finally, you have patient teaching.

Advise allergic patients to wear a Medi -Alert bracelet and impress upon them the golden rule of infectious disease.

Always complete the entire prescribed course of treatment, even if symptoms abate.

Because if they stop early, they only kill the weakest bacteria.

They leave the strongest, most resilient ones behind to multiply and mutate.

You are artificially accelerating the arms race.

Well, we have covered a lot of ground today.

The transpeptidous brick layers, the autolysin wrecking balls, the porin channel armor, the molecular scissors, the altered pvp locks of MRSA, the vital differences in salts, the hapten velcro mechanism of allergies, and the critical bedside assessments.

You are officially ready for this material.

But as you move forward in your career, I want to leave you with a thought experiment.

I love this.

We started by talking about how this microscopic battlefield is constantly shifting.

Bacteria evolved armor.

We found a way through.

They evolved molecular scissors.

We invented decoys to jam them.

They altered their pvp locks.

We switched to completely different drug families.

The elution never stops.

So as you administer these medications on the floor and watch patients recover, ask yourself, what will the fourth major mechanism of bacterial resistance look like?

How will the bacteria inevitably surprise us next?

And how will our pharmacology have to adapt?

The ultimate game of cat and mouse.

Thank you for joining us for this deep dive.

From all of us here at the Last Minute Lecture Team, we sincerely wish you the absolute best of luck on your pharmacology exam.

You've got this.